Acorda Therapeutics (NASDAQ:ACOR):
Acorda (ACOR) Alert: Johnson Fistel Investigates Acorda Therapeutics, Inc.; Investors Suffering Losses Encouraged to Contact Firm.
The company is now up since yesterday’s close of 17.
Acorda Therapeutics, Inc., launched on March 17, 1995, is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS..
The most current P/E ratio is N/A and the market value is 808.73M. As of the last earnings report the EPS was $-1.21 with 46.75M shares outstanding.
Short traders are feeling a little more bullish on shares of Acorda Therapeutics lately considering the fall in short interest. The stock saw a fall in short interest between September 29, 2017 and October 13, 2017 of -12.70%. Short interest decreased 799,313 over that timeframe. Days to cover decreased -4.0 to 7.0 and the percentage of shorted shares was 0.12% on October 13.
Brokerage analysts have weighed in on Acorda Therapeutics. On November 9, 2017 Oppenheimer Holdings released guidance on ACOR setting a rating of “Market Perform”. CIBC updated guidance on ACOR giving it an initial rating of “Market Perform”.
Equity analyst HC Wainwright updated coverage of ACOR by announcing an initial rating of “Buy”. Jefferies Group LLC raised the price target on November 1 changing the forecast from $22.00 to $25.00 with a rating of “Hold”.
On October 31 analysts at J P Morgan Chase & Co released a research note on ACOR and giving a rating of “Hold” and projecting a price target of $24.00. On October 31 Cantor Fitzgerald kept the company rating at “Hold” with a current price target of $18.00.